Sugi Predict

Sugi Predict / Compounds / SCHEMBL6237112

SCHEMBL6237112

SCHEMBL6237112

C#CC1COCCN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ RECQL P46063 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.39
▸ CTSK P43235 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HPGD P15428 1/20 0.35
▸ ATM Q13315 2/20 0.33
▸ PIK3R1 P27986 2/20 0.33
▸ PIK3CA P42336 2/20 0.33
▸ IL1B P01584 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18344821 1.00 SMN1; SMN2 (0.47) SMN1; SMN2USP2RECQLHSD17B10CTSK
SCHEMBL6132726 1.00 SMN1; SMN2 (0.47) SMN1; SMN2USP2RECQLHSD17B10CTSK
SCHEMBL29022290 0.85 USP2 (0.47) SMN1; SMN2USP2RECQLHSD17B10CTSK
SCHEMBL3086236 0.85 USP2 (0.47) SMN1; SMN2USP2RECQLHSD17B10CTSK
SCHEMBL25181600 0.82 SMN1; SMN2 (0.44) SMN1; SMN2USP2RECQLHSD17B10CTSK
SCHEMBL4919669 0.80 HSD17B10 (0.47) SMN1; SMN2USP2RECQLHSD17B10CTSK
SCHEMBL5275535 0.80 HSD17B10 (0.47) SMN1; SMN2USP2RECQLHSD17B10CTSK
SCHEMBL12021701 0.78 USP2 (0.53) SMN1; SMN2USP2RECQLHSD17B10PIK3R1
SCHEMBL925405 0.78 USP2 (0.53) SMN1; SMN2USP2RECQLHSD17B10ALDH1A1
SCHEMBL315706 0.78 USP2 (0.53) SMN1; SMN2USP2RECQLHSD17B10PIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES Clear Creek Bio, Inc. (US) 2025-01-23 — — US disclosed
EP-4323369-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-02-21 — — EP disclosed
CN-117120450-A Thienopyrrole compounds 吉利德科学公司 2023-11-24 — — CN disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-20230365594-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
US-20230365594-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
US-20230365594-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 — — US disclosed
CN-116997549-A Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer 蝎子疗法股份有限公司 2023-11-03 — — CN disclosed
WO-2022221642-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-10-20 — — WO disclosed
WO-2022221642-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-10-20 — — WO disclosed
WO-2022066734-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER SCORPION THERAPEUTICS, INC. (US) 2022-03-31 — — WO disclosed
CN-107849039-B Heteroaryl substituted aminopyridine compounds 百时美施贵宝公司 2020-07-03 — — CN disclosed
EP-3313840-B1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2019-07-24 — — EP disclosed
US-10294229-B2 Heteroaryl substituted aminopyridine compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2019-05-21 — — US disclosed
US-20180186799-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2018-07-05 — — US disclosed
EP-3313840-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS Bristol-Myers Squibb Company (US) 2018-05-02 — — EP disclosed
WO-2016210034-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-29 — — WO disclosed
WO-2005007083-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365594-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 SMN1; SMN2 4502/4885USP2 3870/4885RECQL 765/4885
US-10294229-B2 Heteroaryl substituted aminopyridine compounds IRAK4, IRAK3, IRAK2 SMN1; SMN2 3677/4885USP2 2537/4885RECQL 316/4885
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ERBB2, EGFR, ERBB3 SMN1; SMN2 3294/4885USP2 3142/4885RECQL 2294/4885
US-20180186799-A1 HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS IRAK4, IRAK3, IRAK2 SMN1; SMN2 3677/4885USP2 2537/4885RECQL 316/4885
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES ACE, PREP, PEPD SMN1; SMN2 4601/4885USP2 320/4885RECQL 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.